Clinigen Group plc, of Burton-on-Trent, U.K., said it partnered with Mitsubishi Tanabe Pharma Corp., of Osaka, Japan, to initiate a managed access program (also known as an early access program) in Europe for edaravone, an intravenous treatment for amyotrophic lateral sclerosis. Edaravone, an intravenously administered antioxidant free radical scavengers, is approved in Japan, South Korea and the U.S.